Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis

NCT07852637 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07852637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07852637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis
Lead sponsor
Samsung Medical Center
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2030
Enrollment
2,300 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

active cancer, venous thromboembolism